InnoCare: Will cooperate with multiple global pharmaceutical companies to develop KRAS gene mutation companion diagnostic tests.

Illumina announced that it will collaborate with multiple global pharmaceutical companies to develop companion diagnostic tests based on the TruSight Oncology Comprehensive genomic testing. The continued expansion of companion diagnostics for a wide range of cancers highlights Illumina's commitment to enhancing patient access to precision oncology through standardized and globally applicable testing protocols. The new companion diagnostic collaborations will focus on KRAS gene mutations, which are known to cause uncontrolled cell growth and thus lead to cancer. Companion diagnostic testing based on TSO Comprehensive can help clinical practitioners match patients with approved targeted therapies based on the genetic mutations of their cancer. TSO Comprehensive generates a molecular tumor profile to identify gene mutations that drive cancer growth. In response to these potential mutations, clinical practitioners use companion diagnostic testing to confirm whether patients are eligible for targeted treatment or participation in clinical trials.